抗體的生物素化標(biāo)記實驗要點：

1. 轉(zhuǎn)錄因子7類似物2抗體規(guī)格 如在反應(yīng)混合液中有疊氮鈉或游離氨基存在,會抑制標(biāo)記反應(yīng)。因此,蛋白質(zhì)在反應(yīng)前要對 0.1mol/L碳酸氫鈉緩沖液或0.5mol/L硼酸緩沖液充分透析；

2.所用的NHSB及待生物素化蛋白質(zhì)之間的分子比按蛋白質(zhì)表面的ε-氨基的密度會有所不同,選擇不當(dāng)則影響標(biāo)記的效率,應(yīng)先用幾個不同的分子比來篩選最適條件；

3.用NHSB量過量也是不利的,抗原的結(jié)合位點可能因此被封閉,導(dǎo)致抗體失活；

4.由于抗體的氨基不易接近可能造成生物素化不足,此時可加入去污劑如 Triton x-100, Tween20等；

5.當(dāng)游離ε-氨基(賴氨酸殘基的氨基)存在于抗體的抗原結(jié)合位點時,或位于酶的催化位點時,生物素化會降低或損傷抗體蛋白的結(jié)合力或活性；

6.生物素還可能與不同的功能基團(tuán),如羰基、氨基、巰基、異咪唑基及苯酚基,也可與糖基共價結(jié)合；

7.交聯(lián)反應(yīng)后,應(yīng)充分透析,否則,殘余的生物素會對生物素化抗體與親和素的結(jié)合產(chǎn)生競爭作用；

8.在細(xì)胞的熒光標(biāo)記實驗中,中和親和素的本底低,但由于鏈霉親和素含有少量正電荷,故對某些細(xì)胞可導(dǎo)致高本底。

產(chǎn)品訂購信息：
英文名稱  Anti-TCF7L2 

中文名稱   轉(zhuǎn)錄因子7類似物2抗體規(guī)格 

別    名  E2 2; HMG box transcription factor 4; hTCF 4; Immunoglobulin transcription factor 2; ITF2; SEF2 1; SEF2 1A; SEF2 1B; SEF2; T cell factor 4; T cell specific HMG box; T cell specific transcription factor 4; TCF 4; TCF4; TCF7L2; TCF7L2 protein; hTCF-4; T-cell factor 4; T-cell-specific transcription factor 4; TCF-4; TF7L2_HUMAN; Transcription factor 7-like 2; Transcription factor 4; Transcription factor 7 like 2; Transcription factor 7 like 2 T cell specific HMG box.

濃    度   1mg/1ml

規(guī) 格  0.1ml/100μg 0.2ml/200μg

抗體來源   Rabbit

克隆類型   polyclonal

交叉反應(yīng)   Human, Mouse, Rat, Chicken, Dog, Pig, Cow 

產(chǎn)品類型   一抗  

研究領(lǐng)域    心 染色質(zhì)和核信號 轉(zhuǎn)錄調(diào)節(jié)因子 表觀遺傳學(xué)

蛋白分子量  predicted molecular weight: 68kDa

性    狀   Lyophilized or Liquid

免 疫 原 KLH conjugated synthetic peptide derived from human TCF7L2 

亞    型   IgG

純化方法   affinity purified by Protein A

儲 存 液   0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide

轉(zhuǎn)錄因子7類似物2抗體規(guī)格 產(chǎn)品應(yīng)用    WB=1:100-500 ELISA=1:500-1000 IP=1:20-100 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500

（石蠟切片需做抗原修復(fù)） 

 not yet tested in other applications.

 optimal dilutions/concentrations should be determined by the end user.  

保存條件  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. 

Important Note  This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

產(chǎn)品介紹 TCF-4, transcription factor 4, is a basic helix-turn-helix transcription factor. This protein recognizes an Ephrussi-box ('E-box') binding site ('CANNTG') - a motif first identified in immunoglobulin enhancers. The gene for TCF-4 is expressed predominantly in pre-B-cells, although it is found in other tissues as well. Multiple alternatively spliced transcript variants that encode different proteins have been described. TCF4, also known as TCF7L2, is expressed widely during development. Gene targeting study indicates that it is required to maintain the crypt stem cells of the small intestine. TCF4 has many different splicing isoforms and they are expressed differentially in tissues and in cancers of different stages. Studies also indicate that variant of the TCF4 gene confers an increased risk of type 2 diabetes.

Function : Participates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. Acts as repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2/TCF4 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine.

Subunit : Interacts with TGFB1I1 (By similarity). Interacts with CTNNB1 (via the armadillo repeat); forms stable transcription complex. Interacts with EP300. Interacts with NLK. Interacts with CCDC85B (probably through the HMG box); prevents interaction with CTNNB1. Interacts with TNIK. Interacts with MAD2L2; prevents TCF7L2/TCF4 binding to promZIPK/DAPK3oters, negatively modulating its transcriptional activity. Interacts with ZIPK/DAPK3. Interacts with XIAP/BIRC4 and TLE3. Interacts with DDIT3/CHOP.

Subcellular Location : Nucleus, PML body. Note=Diffuse pattern. Colocalizes with SUMO1 and PIAS4 in a subset of PML (promyelocytic leukemia) nuclear bodies.

Tissue Specificity : Detected in epithelium from small intestine, with the highest expression at the top of the crypts and a gradient of expression from crypt to villus. Detected in colon epithelium and colon cancer, and in epithelium from mammary gland and carcinomas derived therefrom.

Post-translational modifications : In vitro, phosphorylated by TNIK.

Phosphorylated at Thr-201 and/or Thr-212 by NLK. Phosphorylation by NLK at these sites inhibits DNA-binding by TCF7L2/TCF4, thereby preventing transcriptional activation of target genes of the canonical Wnt/beta-catenin signaling pathway.

Polysumoylated. Sumoylation is enhanced by PIAS family members and desumoylation is enhanced by SENP2. Sumoylation/desumoylation regulates TCF7L2/TCF4 transcription activity in the Wnt/beta-catenin signaling pathway without altering interaction with CTNNB1 nor binding to DNA.

DISEASE : Note=Constitutive activation and subsequent transactivation of target genes may lead to the maintenance of stem-cell characteristics (cycling and longevity) in cells that should normally undergo terminal differentiation and constitute the primary transforming event in colorectal cancer (CRC).

Diabetes mellitus, non-insulin-dependent (NIDDM) [MIM:125853]: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels. Note=Disease susceptibility is associated with variations affecting the gene represented in this entry.

Similarity : Belongs to the TCF/LEF family.

Contains 1 HMG box DNA-binding domain.

Database links : UniProtKB/Swiss-Prot: Q9NQB0.2

主要用于的研究，TCF7L2基因可能存在雙重效應(yīng)，抑制β細(xì)胞代償，減小分泌的退化。

抗體的鑒定：

1）轉(zhuǎn)錄因子7類似物2抗體規(guī)格 抗體的效價鑒定：不管是用于診斷還是用于,制備抗體的目的都是要求較高效價。不同的抗原制備的抗體,要求的效價不一。鑒定效價的方法很多,包括有試管凝集反應(yīng),瓊脂擴散試驗,酶聯(lián)免疫吸附試驗等。常用的抗原所制備的抗體一般都有約成的鑒定效價的方法,以資比較。如制備抗抗體的效價,一般就采用瓊脂擴散試驗來鑒定。

2）抗體的特異性鑒定：抗體的特異性是指與相應(yīng)抗原或近似抗原物質(zhì)的識別能力?？贵w的特異性高,它的識別能力就強。衡量特異性通常以交叉反應(yīng)率來表示。交叉反應(yīng)率可用競爭抑制試驗測定。以不同濃度抗原和近似抗原分別做競爭抑制曲線,計算各自的結(jié)合率,求出各自在IC50時的濃度,并按公式計算交叉反應(yīng)率。 

如果所用抗原濃度IC50濃度為pg/管,而一些近似抗原物質(zhì)的IC50濃度幾乎是無窮大時,表示這一抗血清與其他抗原物質(zhì)的交叉反應(yīng)率近似為0,即該血清的特異性較好。

3）抗體親和力：是指抗體和抗原結(jié)合的牢固程度。親和力的高低是由抗原分子的大小,抗體分子的結(jié)合位點與抗原決定簇之間立體構(gòu)型的合適度決定的。有助于維持抗原抗體復(fù)合物穩(wěn)定的分子間力有氫鍵,疏水鍵,側(cè)鏈相反電荷基因的庫侖力,范德華力和空間斥力。親和力常以親和常數(shù)K表示,K的單位是L/mol。抗體親和力的測定對抗體的篩選,確定抗體的用途,驗證抗體的均一性等均有重要意義。

GABA/BSA γ1氨基偶聯(lián)血清白蛋白Multi-class antibodies規(guī)格： 1mg

Anti-HER4/ErbB4 HER4抗體Multi-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh OAT-1/SLC22A6 陰離子轉(zhuǎn)運蛋白-1抗體 規(guī)格 0.1ml

HRP/Horseradish Peroxidase 辣根過氧化物酶(辣根酶) 10mg

TRP2 英文名稱： 酪酸酶相關(guān)蛋白2抗體 0.2ml

c-Maf 英文名稱： 原癌基因cMAF抗體 0.2ml

Anti-HER4/ErbB4 HER4抗體Multi-class antibodies規(guī)格： 0.2ml

cAMP ELISA Kit 大鼠環(huán)磷酸腺苷Multi-class antibodies規(guī)格： 48T

Anti-ARC/FITC 熒光素標(biāo)記ARC抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Rhesus antibody Rh FAM154A FAM154A蛋白抗體 規(guī)格 0.2ml

E-Cad(Mouse E-Cadherin) ELISA Kit 小鼠E鈣粘著蛋白/上皮性鈣黏附蛋白 96T

Angiotensin II Type 2 Receptor 英文名稱： 緊張素Ⅱ2型受體相互作用蛋白抗體 0.1ml

Annexin A11 英文名稱： 膜粘連蛋白11抗體 0.2ml

Anti-ARC/FITC 熒光素標(biāo)記ARC抗體IgGMulti-class antibodies規(guī)格： 0.2ml

Anti-STEAP1/FITC 熒光素標(biāo)記跨膜上皮抗原1抗體IgGMulti-class antibodies規(guī)格： 0.2ml

GIP (Gastric Inhibitory polypeptide) 胃泌素抑制肽(抗原)Multi-class antibodies規(guī)格： 0.5mg

人胎盤生長因子相關(guān)抗體 Anti-PLGF 0.1ml

Phospho-Stathmin (Ser16) 英文名稱： 磷酸化原癌基因蛋白18抗體 0.1ml

E-Selectin 英文名稱： E選擇素抗體 0.1ml

Rhesus antibody Rh Phospho-mTOR (Ser2481) 磷酸化雷帕霉素靶蛋白抗體 規(guī)格 0.1ml

GIP (Gastric Inhibitory polypeptide) 胃泌素抑制肽(抗原)Multi-class antibodies規(guī)格： 0.5mg

大鼠內(nèi)毒素(Endotoxin)ELISA試劑盒 ，英文名： Endotoxin ELISA Kit

人白介素1β(IL-1β)ELISA檢測試劑盒HumanIerleukin1β,IL-1βELISAKit 96T/48T

魚17-羥孕烯醇酮免疫試劑盒 Fish 17-hydroxypregnenolone ELISA kit

CLIAKitforPAP(MouseProstaticAcidPhosphatase)ELISAKit小鼠酸性磷酸酶規(guī)格：48T/96T

水溶性四氮唑-8比色法細(xì)胞繁殖測定試劑盒500次

ELISAKitmIgA人表面膜免疫球蛋白A規(guī)格：48T/96T

大鼠成纖維細(xì)胞生長因子11(FGF11)ELISA試劑盒 ，英文名： FGF11 ELISA Kit

Human XC chemokine receptor 1 (XCR1) ELISA Kit 人XC趨化因子受體1(XCR1)ELISA試劑盒

RatCarboxyterminalpropeptideoftypeⅠprocollagen,PⅠCPELISAKit 大鼠Ⅰ型前膠原羧基端肽(PⅠCP)ELISA試劑盒 96T/48T 進(jìn)口分裝

CLIAKitforCr(MouseCrosslaps)ELISAKit小鼠骨膠原交聯(lián)規(guī)格：48T/96T

細(xì)胞緊張素Ⅰ轉(zhuǎn)化酶2(ACE2)活性熒光共振能量轉(zhuǎn)移法(FRET)定量檢測試劑盒20次

RatCystatinC,Cys-CELISAKit大鼠半胱氨酸蛋白酶抑制劑/胱抑素C(Cys-C)ELISA試劑盒規(guī)格：96T/48T

轉(zhuǎn)錄因子7類似物2抗體規(guī)格 大鼠端粒酶(TE)ELISA試劑盒 ，英文名： TE ELISA Kit

Porcine growth hormone (GH) ELISA Kit 豬生長激素(GH)ELISA試劑盒

植物源性成分(RBCL)核酸檢測試劑盒(PCR-熒光探針法) 48T

CLIAKitforLTC4ELISAKit大鼠白三烯C4規(guī)格：48T/96T

體液總脂蛋白膽固醇(TotalL-Cholesterol)酶連續(xù)循環(huán)比色法定量檢測試劑盒20次

ELISAKitHSP-70雞熱休克蛋白70規(guī)格：48T/96T